Tern SVV Fund undertakes its first investment

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has noted that following the agreement for Tern to participate in the new Sure Valley Ventures UK Software Technology Fund, announced on 2 March 2022, the new SVV Fund has undertaken its first investment.

The SVV Fund has led a £2 million seed investment round, with the SVV Fund providing a £1 million investment in RETìníZE Limited, an award-winning creative-technology company based in Belfast, Northern Ireland.  RETìníZE is developing an innovative software product, Animotive, that is harnessing virtual reality technologies to transform the 3D animation production process.  The investment is designed to drive RETìníZE’s growth plan for the next two-years and the global rollout of Animotive.

Tern’s contribution to the SVV Fund’s investment in RETìníZE will be covered by the approximately £90,000 initially invested by Tern in the SVV Fund, as previously announced.

The SVV Fund are joined in RETìníZE’s investment round by investors from the UK, USA, Ireland and the Netherlands, including: TechStart Ventures, who are following on from their 2019 pre-seed investment; VGC Partners; Clarendon/Co-fund NI; Lonely Horse Investments; Bertram van Munster and Elise Doganieri, the multi Emmy award-winning producers behind the CBS hit show ‘the Amazing Race’; and Ben Morrow, Senior Product Manager, Adobe Aero (Adobe’s AR creation tool).

RETìníZE CEO, Phil Morrow, said: “We are thrilled to have Sure Valley on board as our lead investor – they have a deep knowledge of the creative tech sector and what impressed us most was the time they took to really understand and challenge our long-term goals and objectives.  This investment will supercharge our growth trajectory and will allow us to take Animotive to the international market.”

Sure Valley Ventures Principal, Isabelle O’Keeffe, said: “We are delighted to be able to support RETìníZE as the first investment of our recently launched software fund, as it enters this exciting new phase. We recognise that the immersive software sector is poised for exponential growth, and the plans that RETìníZE has for Animotive will position the company at the forefront of this expansion. We will continue to identify new opportunities in Metaverse, AI and Cybersecurity as we deploy our Fund II capital, with a focus on companies, like RETìníZE, which are bringing a disruptive innovation to market.”

Commenting, Al Sisto, CEO of Tern said: “We are delighted to see the SVV Fund make their first investment.  In RETìníZE they are investing in an exciting company developing innovative technology that fits very well with Tern’s existing participation in the virtual reality space. As a member of the SVV Fund’s Investor Committee, I look forward to working with RETìníZE, with a view to benefiting both RETìníZE and Tern’s wider network of companies.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search